Our Focus

Our team at Shantilal Shanghvi Eye Institute (SSEI) let by Dr. Jay Sheth, Head of Retina and Clinical Research, in collaboration with other centers in India, set out to understand how the newest retinal injection, faricimab, works for patients here in India. Approved globally as the latest in a line of eye injections and available in India since 2024, faricimab promises longer‑lasting results than earlier treatments. We’re proud to be among the first in the country to track its real‑world impact.

What is it about?

About 50 people with diabetes‑related eye swelling, age‑related vision loss (macular degeneration), or eye vein blockages got faricimab injections. We evaluated their eyes over six months to track their vision and improvement in retinal parameters on scans. We noted:

• Longer‑Lasting Clarity: Faricimab stayed active inside the eye for a longer stretch, so many patients needed fewer visits than with older injections.
• Noticeable Vision Gains: Most people reported being able to read, watch TV, and navigate their day more easily.
• Reduced swelling at the back of the eye (retina), helping to protect vision-critical cells.
• Safe and Well‑Tolerated: We saw no serious inflammation or other major side effects.

Why it matters

Conditions like diabetic swelling and abnormal vessel growth are leading causes of vision loss worldwide. By showing that this newer molecule works safely and effectively in our own Indian patients, and lasts longer between treatments, we’re helping doctors feel confident in choosing faricimab. Fewer injections, steadier vision, and less swelling all translate to a better quality of life for people who rely on these therapies to keep their sight.

Citation

Agrawal V, Gupta A, Agrawal V, Sheth JU. Faricimab Outcomes in Chorioretinal Disorders: Indian Real-World Analysis (FOCUS Study). Clin Ophthalmol. 2025 Jun 12;19:1855-1862. doi: 10.2147/OPTH.S521384.